JP5902673B2 - 眼疾患の処置のためのキノンの製剤 - Google Patents

眼疾患の処置のためのキノンの製剤 Download PDF

Info

Publication number
JP5902673B2
JP5902673B2 JP2013508167A JP2013508167A JP5902673B2 JP 5902673 B2 JP5902673 B2 JP 5902673B2 JP 2013508167 A JP2013508167 A JP 2013508167A JP 2013508167 A JP2013508167 A JP 2013508167A JP 5902673 B2 JP5902673 B2 JP 5902673B2
Authority
JP
Japan
Prior art keywords
formulation
disease
formula
quinone
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013508167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013525443A (ja
JP2013525443A5 (https=
Inventor
ガイ エム． ミラー，
ガイ エム． ミラー，
Original Assignee
エジソン ファーマシューティカルズ， インコーポレイテッド
エジソン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エジソン ファーマシューティカルズ， インコーポレイテッド, エジソン ファーマシューティカルズ， インコーポレイテッド filed Critical エジソン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2013525443A publication Critical patent/JP2013525443A/ja
Publication of JP2013525443A5 publication Critical patent/JP2013525443A5/ja
Application granted granted Critical
Publication of JP5902673B2 publication Critical patent/JP5902673B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013508167A 2010-04-27 2011-04-26 眼疾患の処置のためのキノンの製剤 Expired - Fee Related JP5902673B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32854610P 2010-04-27 2010-04-27
US61/328,546 2010-04-27
US39369310P 2010-10-15 2010-10-15
US61/393,693 2010-10-15
PCT/US2011/033983 WO2011137126A1 (en) 2010-04-27 2011-04-26 Formulations of quinones for the treatment of ophthalmic diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016046881A Division JP6266674B2 (ja) 2010-04-27 2016-03-10 眼疾患の処置のためのキノンの製剤

Publications (3)

Publication Number Publication Date
JP2013525443A JP2013525443A (ja) 2013-06-20
JP2013525443A5 JP2013525443A5 (https=) 2014-06-19
JP5902673B2 true JP5902673B2 (ja) 2016-04-13

Family

ID=44861894

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013508167A Expired - Fee Related JP5902673B2 (ja) 2010-04-27 2011-04-26 眼疾患の処置のためのキノンの製剤
JP2016046881A Expired - Fee Related JP6266674B2 (ja) 2010-04-27 2016-03-10 眼疾患の処置のためのキノンの製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016046881A Expired - Fee Related JP6266674B2 (ja) 2010-04-27 2016-03-10 眼疾患の処置のためのキノンの製剤

Country Status (13)

Country Link
US (2) US20130109759A1 (https=)
EP (1) EP2563352A4 (https=)
JP (2) JP5902673B2 (https=)
CN (2) CN105147651A (https=)
AU (1) AU2011245384C1 (https=)
BR (1) BR112012027543A8 (https=)
CA (1) CA2797581A1 (https=)
EA (1) EA201201465A1 (https=)
MX (1) MX337594B (https=)
MY (1) MY183449A (https=)
SG (2) SG185046A1 (https=)
WO (1) WO2011137126A1 (https=)
ZA (1) ZA201208535B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033092A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
EP2471530B1 (en) * 2005-06-01 2017-01-11 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US9278085B2 (en) 2006-02-22 2016-03-08 Edison Pharmaceuticals, Inc. Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
WO2009061744A2 (en) 2007-11-06 2009-05-14 Edison Pharmaceuticals, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
EA023618B1 (ru) * 2008-01-08 2016-06-30 Эдисон Фармасьютикалз, Инк. Производные (гет)арил-п-хинона для лечения митохондриальных болезней
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
WO2009158348A1 (en) * 2008-06-25 2009-12-30 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
EP2344142B1 (en) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
EP2362726B1 (en) 2008-10-14 2018-08-08 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
CA2741767C (en) 2008-10-28 2017-09-12 Ptc Therapeutics, Inc. Process for the production of alpha-tocotrienol and derivatives
PL2424495T3 (pl) 2009-04-28 2018-06-29 Bioelectron Technology Corporation Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu
DK2470168T3 (en) * 2009-08-26 2018-05-07 Bioelectron Tech Corp PROCEDURES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCAM
AU2011238525A1 (en) * 2010-04-06 2012-11-08 Edison Pharmaceuticals, Inc. Treatment of Ataxia Telangiectasia
CA2797581A1 (en) * 2010-04-27 2011-11-03 Edison Pharmaceuticals, Inc. Formulations of quinones for the treatment of ophthalmic diseases
WO2012174286A1 (en) 2011-06-14 2012-12-20 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
JP2014520894A (ja) 2011-07-19 2014-08-25 エジソン ファーマシューティカルズ， インコーポレイテッド 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法
CA2883879A1 (en) 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US10189830B2 (en) 2013-03-15 2019-01-29 Bioelectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
AU2015364640B2 (en) 2014-12-16 2020-08-13 Ptc Therapeutics, Inc. Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
EP3390377B1 (en) 2015-12-16 2026-03-25 PTC Therapeutics, Inc. Improved methods for enriching alpha-tocotrienol from mixed tocol compositions
WO2017106803A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
WO2019070917A1 (en) * 2017-10-03 2019-04-11 The Schepens Eye Research Institute, Inc. COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE DEGENERATION OF RETINAL PIGMENT EPITHELIUM AND METHODS USING SAME
KR20210076956A (ko) 2018-10-17 2021-06-24 피티씨 테라퓨틱스, 인크. α-시누클레인병증, 타우병증 및 기타 장애를 억제 및 치료하기 위한 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온
CN114126640B (zh) * 2019-05-28 2024-10-29 爱儿安制药有限公司 治疗视网膜病变的组合物和方法
PE20240893A1 (es) 2021-07-08 2024-04-24 Ptc Therapeutics Inc Composiciones farmaceuticas que comprenden 2,3,5-trimetil-6-nonilciclohexa-2,5-dien-1,4-diona
WO2025231245A1 (en) * 2024-05-02 2025-11-06 Stealth Biotherapeutics Inc. Use of substituted 1,4 benzoquinones to treat alpha-synucleinopathies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2471530B1 (en) * 2005-06-01 2017-01-11 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
EP1924292A2 (en) * 2005-09-16 2008-05-28 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents
US9278085B2 (en) * 2006-02-22 2016-03-08 Edison Pharmaceuticals, Inc. Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
EP2344142B1 (en) * 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
DK2470168T3 (en) * 2009-08-26 2018-05-07 Bioelectron Tech Corp PROCEDURES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCAM
AU2011238525A1 (en) * 2010-04-06 2012-11-08 Edison Pharmaceuticals, Inc. Treatment of Ataxia Telangiectasia
CA2797581A1 (en) * 2010-04-27 2011-11-03 Edison Pharmaceuticals, Inc. Formulations of quinones for the treatment of ophthalmic diseases

Also Published As

Publication number Publication date
BR112012027543A2 (pt) 2019-05-28
JP2013525443A (ja) 2013-06-20
CN102985083A (zh) 2013-03-20
EA201201465A1 (ru) 2013-04-30
ZA201208535B (en) 2016-06-29
EP2563352A1 (en) 2013-03-06
AU2011245384A1 (en) 2012-12-06
MY183449A (en) 2021-02-18
US20130109759A1 (en) 2013-05-02
US20170354618A1 (en) 2017-12-14
SG10201801321XA (en) 2018-04-27
AU2011245384B2 (en) 2016-02-18
CN105147651A (zh) 2015-12-16
JP2016106144A (ja) 2016-06-16
JP6266674B2 (ja) 2018-01-24
MX2012012518A (es) 2012-12-17
AU2011245384C1 (en) 2016-09-01
EP2563352A4 (en) 2013-11-13
MX337594B (es) 2016-03-11
BR112012027543A8 (pt) 2019-12-03
WO2011137126A1 (en) 2011-11-03
CA2797581A1 (en) 2011-11-03
SG185046A1 (en) 2012-12-28

Similar Documents

Publication Publication Date Title
JP6266674B2 (ja) 眼疾患の処置のためのキノンの製剤
AU2011245384B9 (en) Formulations of quinones for the treatment of ophthalmic diseases
JP2017193594A (ja) 眼科疾患を治療するためのトコトリエノールキノンの製剤
CA2777479C (en) Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
US20120136048A1 (en) Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases
HK1168028B (en) Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
HK1168028A (en) Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150323

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150924

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160310

R150 Certificate of patent or registration of utility model

Ref document number: 5902673

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees